2024 ASH Annual Meetingdoi:10.1016/S2352-3026(25)00005-5Daniela MarínLan-Lan SmithElsevier LtdThe Lancet Haematology
MENIN抑制剂在急性白血病治疗中的突破性进展:2024ASH年会最新临床数据解读 《Experimental Hematology & Oncology》:MENIN inhibitor-based therapy in acute leukemia: latest updates from the 2024 ASH annual meeting 编辑推荐: 针对KMT2Ar/NPM1m急性白血病(AL)患者缺乏有效靶向治疗的难题,研究人员聚焦MENIN抑制剂(ME...
全球血液学盛会第64届美国血液学会年会(64th ASH Annual Meeting)将于2022年12月10-13日在美国新奥尔良举行,中国基因编辑药物头部企业广州瑞风生物科技有限公司(Reforgene Medicine,下称“瑞风生物”)的β-地中海贫血基因编辑治疗产品RM-001最新临床研究成果将在2022 ASH年会上报道,这是继2022年6月欧洲血液学年会(EHA...
for the treatment of cancer, today announced the presentation of CD38-SADA in Non-Hodgkin Lymphoma (NHL) preclinical data and trial in progress posters at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition being held on December 7 –10, 2024, in San Diego,...
CS5001 is so far the first anti-ROR1 ADC known to show clinical anti-tumor activity in both solid tumors and lymphomas. Preliminary data from the first-in-human study presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated that CS5001 is well-tolerated ...
66th American Society of Hematology Annual Meeting and Exposition (ASH 2024) Booth #105NinaMaria, living with thalassemia Agios ASH 2024 Data Room Agios is presenting new data on mitapivat and tebapivat (AG-946), the company’s two PK activators, at ASH 2024. Key presentations and publica...
(R/R) CD19-positive B-cell malignancies at the 2024 American Society of Hematology (ASH) Annual Meeting. Additionally, the Company announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX112 for...
stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today featured a wealth of clinical data for Aptose’s lead compound tuspetinib (TUS) in a poster presentation at the 66thAmerican Society of Hematology (ASH) Annual Meeting ...
2024年12月9日,中国北京——诺诚健华(上交所代码:688428;香港联交所代码:09969)新型BTK抑制剂奥布替尼治疗血液瘤的多项研究数据在正在美国圣地亚哥举办的第66届美国血液学会(ASH)年会上进行了公布。 海报展示 1. 奥布替尼治疗对布鲁顿酪氨酸激酶抑制剂(BTKi)不耐受的惰性非霍...
Install the 2024 ASH Annual Meeting conference app as your full featured guide to manage your conference attendance. Event App features include: • Native app…